New Trial of Constipation Predominant IBS Treatment Now Recruiting at 69 Centers in U.S. & Canada

1 Star2 Stars3 Stars4 Stars5 Stars (192 votes, average: 3.10 out of 5)
Loading...

This Phase 2b trial involving a drug to be taken orally for symptom relief of constipation predominant IBS (ClinicalTrials.gov number NCT00547469) is enrolling female patients only – at 69 sites in more than 20 U.S. states and across Canada.

The drug – pumosetrag (DDP733) – is said to mimic the effect of the neurotransmitter serotonin, which is known to be involved in control of the gastrointestinal system.

For details of this large-scale pharmaceutical firm-sponsored study, visit the study listing at ClinicalTrials.gov.

For those who may be interested in participating, the ClinicalTrials.gov description includes a link to a separate site with more information about the trial and the trial sites (http://www.pictureibs.com) – plus an interactive eligibility-screening questionnaire.

1 Star2 Stars3 Stars4 Stars5 Stars (192 votes, average: 3.10 out of 5)
Loading...



One thought on “New Trial of Constipation Predominant IBS Treatment Now Recruiting at 69 Centers in U.S. & Canada”

  1. diegolady says:

    Why is 65 the magical cut off age for people doing drug trials? Except for Fibro and some arthritis, I am in good health for my age (74). Goodness knows, aren’t we the ones needing most of this stuff?

Leave a Reply